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Dominance of vaccine serotypes in 
pediatric invasive pneumococcal 
infections in Portugal (2012–2015)
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We evaluated the impact of continued 13-valent pneumococcal conjugate vaccine (PCV13) use in 
the private market (uptake of 61%) in pediatric invasive pneumococcal disease (pIPD) in Portugal 
(2012–2015). The most frequently detected serotypes were: 3 (n = 32, 13.8%), 14 (n = 23, 9.9%), 1 
(n = 23, 9.9%), 7F (n = 15, 6.4%), 19A (n = 13, 5.6%), 6B and 15B/C (both n = 12, 5.2%), and 24F, 10A 
and 12B (all with n = 10, 4.3%). Taken together, non-PCV13 serotypes were responsible for 42.2% of 
pIPD with a known serotype. The use of PCR to detect and serotype pneumococci in both pleural and 
cerebrospinal fluid samples contributed to 18.1% (n = 47) of all pIPD. Serotype 3 was mostly detected 
by PCR (n = 21/32, 65.6%) and resulted from a relevant number of vaccine failures. The incidence of 
pIPD varied in the different age groups but without a clear trend. There were no obvious declines of the 
incidence of pIPD due to serotypes included in any of the PCVs, and PCV13 serotypes still accounted for 
the majority of pIPD (57.8%). Our study indicates that a higher vaccination uptake may be necessary 
to realize the full benefits of PCVs, even after 15 years of moderate use, and highlights the importance 
of using molecular methods in pIPD surveillance, since these can lead to substantially increased case 
ascertainment and identification of particular serotypes as causes of pIPD.
The introduction of pneumococcal conjugate vaccines (PCVs) into routine infant immunization programs world-
wide has led to significant decreases in overall incidence of invasive pneumococcal disease (IPD), both in children 
and in adults1–5. Moreover, massive changes in the distribution of Streptococcus pneumoniae serotypes were also 
noted, with major decreases in the incidence of IPD caused by vaccine serotypes (VTs), i.e. those included in PCV 
formulations1,2,6,7. However, this was accompanied in some cases by an increase in the incidence of IPD due to 
non-vaccine serotypes (NVTs)5,8,9. Additionally, antimicrobial susceptibility may also be affected by the use of 
PCVs since these target serotypes frequently associated with antimicrobial resistance10,11.
In Portugal, although available only in the private market, the introduction of the 7-valent pneumococcal con-
jugate vaccine (PCV7) in 2001 led to significant changes in the serotypes responsible for pediatric IPD (pIPD)2. 
Among the most relevant changes was the rise of non-PCV7 serotypes 1, 7F and 19A as major causes of pIPD12. 
During this period uptake peaked at 75% around 20081. In mid-2009, PCV10 became available, including PCV7 
serotypes and additionally serotypes 1, 5 and 7F. Soon after this, in early 2010, PCV13 was introduced in Portugal, 
further including serotypes 3, 6A and 19A, and became the leading vaccine used in Portugal.
Despite a decline in PCV uptake to 62% in 2012, which remained stable until 2014 at 61%13, the introduction 
of higher valency vaccines was accompanied by declines of pIPD incidence, with a decrease from 8.19 cases per 
100,000 inhabitants in 2008–2009 to 4.52 per 100,000 inhabitants in 2011–20121. Despite PCV7 use since 2001, 
this decrease was mainly due to decreases in the number of cases due to serotypes included in the newest vac-
cines, particularly serotype 1 and 19A in older and younger children, respectively, and not to further reductions in 
the number of cases due to PCV7 serotypes, including in children under 2 years of age. That study also suggested 
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that some of the serotype changes may not have been triggered by vaccination1, emphasizing the importance of 
the natural fluctuations of serotypes and the need to perform continuous epidemiological surveillance.
In July 2015, PCV13 was introduced in the National Immunization Plan (NIP), for children born after January 
2015, with doses given at 2, 4 and 12 months of age. The aims of this work were to determine the incidence of 
pIPD in Portugal, as well as serotype distribution and susceptibility patterns among the pneumococcal popula-
tion between July 2012 and June 2015, just prior to the introduction of PCV13 in the NIP.
Results
Isolate collection. Between July 2012 and June 2015, a total of 259 cases of pIPD were reported. Table 1 
summarizes their distribution by age and epidemiological year while Fig. 1 presents the annual incidence of pIPD 
by age group. We found no temporal and geographic clustering of cases which could suggest the existence of out-
breaks. Although there were variations in the incidence of pIPD in all age groups these did not show clear trends 
(Table S1). For 27 cases (10.4%) neither the isolate nor a patient sample was sent to the central laboratory for 
characterization. A total of 185 isolates (79.7%) and 47 samples (20.2%) of LCR (n = 6) or pleural fluid (n = 41) 
positive for S. pneumoniae were available for further characterization. Available isolates were recovered from 
blood (n = 149, 80.6%), CSF (n = 25, 13.4%), pleural fluid (n = 7, 3.8%), and synovial fluid (n = 4, 2.2%).
Serotype distribution. Among the 232 isolates and patient samples 39 different capsular types were 
detected, including samples for which the serotype could not be unambiguously determined– 7F/7A (n = 3), 
25A/38 (n = 2), serogroup 6 (n = 1), 33F/33A/37 (n = 1), 29/35B (n = 1), as well as non-typable isolates (Figs 2 
and 3). This translated into a high serotype diversity (SID = 0.943; CI95% 0.933 to 0.954). The most frequent 
serotypes, which accounted for 69% of all pIPD in the study period, were serotypes 3 (n = 32, 13.8%), 14 (n = 23, 
9.9%), 1 (n = 23, 9.9%), 7F (n = 15, 6.4%), 19A (n = 13, 5.6%), 6B and 15B/C (both n = 12, 5.2%), and 24F, 10A 
and 12B (all with n = 10, 4.3%). Overall pIPD due to the serotypes included in PCV13 remained significant, 
accounting for 57.8% (21.6% PCV7) of the isolates and patient samples. When considering individual serotypes 
(n > 5) in all age groups, we noted significant decreases in the number of cases from 2012–2013 to 2014–2015 
of serotypes 1 and 15B/C, and an increase of serotype 14, but none of these changes was statistically supported 
(Table 2).
To estimate the incidence of pIPD due to individual serotypes, the cases for which no isolate was available 
were assumed to have the same serotype distribution as that found among isolates from the same epidemiolog-
ical year and age group. Since the molecular serotyping technique used on culture negative samples comprised 
all the serotypes included in PCV13, when a serotype could not be determined by this method, the case was 
Epidemiological yearsa
Cases/number of missing samples, by age group
0–11 months 12–23 months 2–4 years 5–17 years Total
2012–2013 21/2 15/2 30/2 19/3 85/9
2013–2014 33/5 9/1 23/0 19/1 84/7
2014–2015 20/3 22/2 23/2 25/4 90/11
Total 74/10 46/5 76/4 63/8 259/27
Table 1. Cases and missing samples from invasive pneumococcal disease from patients <18 yrs, Portugal, July 
2012–June 2015. aFrom week 26 of one year to week 25 of the following year.
Figure 1. Incidence of invasive pneumococcal disease in children and adolescents in Portugal (2012–2013 to 
2014–2015). The 95% confidence intervals for the incidence estimates are indicated.
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considered caused by an NVT serotype. Cases whose serotype remained undetermined (7F/7A, 25A/38, sero-
group 6, 33F/33A/37, 29/35B) and non-typable isolates were considered NVTs. As with overall pIPD incidence, 
in some age groups there were variations in the incidence of pIPD due to the serotypes included in each of the 
conjugate vaccine formulations, but these showed no clear trend (Fig. 4).
Antimicrobial susceptibility. Susceptibility to antimicrobials was tested among the 185 available isolates 
and is summarized in Figs 2 and 3 and Table 3.
Overall 43 isolates (23.2%) were nonsusceptible to penicillin (PNSP) – 34 (18.4%) expressed low-level resist-
ance and 9 (4.8%) high-level resistance. Considering the current CLSI breakpoints for parenteral penicillin14, 6 
isolates (24%) from the CSF would have been considered resistant and 6 isolates (3.8%) from non-meningitis 
Figure 2. Number of samples representing serotypes present in conjugate vaccines causing invasive infections 
in Portugal (2012–2013 to 2014–2015). The number of samples representing each serotype in each of the 
age groups considered is indicated. Isolates presenting both erythromycin resistance and penicillin non-
susceptibility (EPNSP) are represented by red bars. Penicillin non-susceptible isolates (PNSP) are indicated by 
orange bars. Erythromycin resistant isolates (ERSP) are indicated by yellow bars. Isolates susceptible to both 
penicillin and erythromycin are represented by green bars. Cases where no sample was available or where 
pneumococci were detected exclusively by PCR and for which susceptibility is unknown, are indicated by white 
bars. The serotypes included in each of the conjugate vaccines are indicated by the arrows. NVT – non-vaccine 
serotypes, i.e., serotypes not included in any of the currently available conjugate vaccines (PCV7, PCV10 and 
PCV13). The values indicated below the arrows are the proportion of each group in the overall cases (n = 259).
Figure 3. Number of samples representing serotypes not present in conjugate vaccines causing invasive 
infections in Portugal (2012–2013 to 2014–2015). See the legend of Fig. 2. NT – Non-typeable. Some serotypes 
could not be unambiguously determined and are indicates as such (see text). Among the 12 isolates identified as 
15B/C, 8 were originally typed as 15B and 4 isolates were typed as 15C.
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cases would have been considered nonsusceptible, all intermediately resistant. Resistance to erythromycin (ERP) 
was found in 42 isolates (22.7%), of which 35 isolates (83.3%) expressed the constitutive MLSB phenotype and 7 
(16.7%) the M phenotype. All isolates were susceptible to levofloxacin, vancomycin and linezolid. The simultane-
ous expression of erythromycin resistance and penicillin non-susceptibility (EPNSP) was found in 13.5% of the 




1 12 5 6
3 12 10 10
6B 5 4 3
7Fb 5 3 6
10 A 3 5 2
12B 0 8 2
14 5 6 12
15B/C 7 3 2
19 A 5 1 7
24 F 5 2 3
Table 2. Serotypes responsible for ≥10 IPD cases with a known serotype. aEpidemiological years: from week 26 
of one year to week 25 of the following year. bThe three cases in which the determined serotype was 7 F/7A are 
not included.
Figure 4. Incidence of invasive pneumococcal disease in children and adolescents in Portugal (2011–2012 to 
2014–2015). NVT – non-vaccine serotypes.
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Serotype 14 contributed greatly to erythromycin resistance (31.0%) and to penicillin nonsusceptibility (46.5%) 
(Fig. 2). Serotypes included in PCV7 represented 77.8%, 41.1% and 56.0% of PNSP, ERSP and EPNSP, respec-
tively, while serotypes included in PCV13 constituted 77.8%, 52.9% and 68.0%, respectively.
Discussion
pIPD incidence varied only modestly and without a clear trend in 2012–2015, in contrast to the significant 
declines in pIPD incidence seen in 2008–2012, particularly among the younger groups1. As was seen previously, 
PCV7 serotypes remain important causes of pIPD (with incidences varying between 0.94–1.12 cases/100,000 
in 2012–2015), with the slower uptake and lower vaccination coverage reached in Portugal, when compared to 
countries where PCV7 was introduced in the NIP, and the high resistance of isolates expressing PCV7 serotypes, 
particularly to penicillin and the macrolides (77% of all PNSP and 41% of all ERP), possibly being important 
factors for their persistence1.
The serotype dynamics were different in the various age groups, but the dominant feature of the 2012–2015 
period was serotype instability, with the incidence of the serotypes included in the different PCVs and NVTs 
fluctuating without a definite trend in the various age groups. This may be due to the use of PCVs outside of the 
NIP and the existence of a considerable number of unvaccinated children that remain susceptible to VT disease. 
The variable yearly dissemination of PCV serotypes in the latter group could account for some of the fluctuations 
seen. In neighboring Spain, the switch in Madrid from administering PCV13 within the NIP to the private sector, 
with a concomitant decline in uptake from 95% to 67–73% (similar to the one in Portugal), led to a stagnation in 
the decline of PCV13 pIPD15, suggesting that a high vaccination uptake is needed to reap the full benefits of PCV 
use seen elsewhere16,17.
Although the number of pIPD cases identified solely by molecular methods was not very different from that in 
2008–20121, the proportion was higher in 2012–2015 (n = 41/471 = 8.6% in 2008–2012 versus n = 47/259 = 18.1% 
in 2012–2015). In contrast to our last study, in this period we serotyped by molecular methods samples from 
which no isolate was recovered. This resulted in a significant improvement in the identification of the serotypes 
causing complicated pneumonias, in which pneumococci were frequently identified exclusively by molecular 
methods in pleural fluid, and which constituted 20.2% of all samples with serotype information. Serotype 3, the 
most frequently detected serotype in 2012–2015 (Fig. 2 and Table 2) was predominantly detected in pleural fluid 
samples by molecular methods (n = 21/32, 65.6%) and, as reported and discussed elsewhere13, was frequently 
associated with vaccine failures. The persistence of serotype 3 despite vaccination and its association with compli-
cated pneumonia, together with the decline of other vaccine serotypes associated with other disease presentations 
and positive cultures, is potentially contributing to the increase in the relative importance of molecular methods 
in identifying pIPD cases. Serotype 3 was not among the most prevalent serotypes in previous years1,2,12, but 
this would have also been the case in this study if molecular methods had not been used for serotyping directly 
from culture negative patient samples. A recent study from England and Wales looking at IPD in all age groups, 
reported that PCR-confirmed cases were a minority of all IPD (<4%) and were therefore excluded from the anal-
ysis performed by the authors17. However, in our context molecular methods did contribute for the identification 
Antibiotica









PENc 17 (28.8) 12 (33.3) 8 (16.3) 6 (14.6)
   MIC90 1.5 1.5 1 0.094
   MIC50 0.016 0.016 0.016 0.016
CROc 4 (6.8) 1 (2.8) 0 (0) 0 (0)
   MIC90 1 1 0.75 0.064
   MIC50 0.02 0.023 0.016 0.016
CTXc 2 (3.4) 2 (5.6) 0 (0) 0 (0)
   MIC90 0.75 0.75 0.5 0.094
   MIC50 0.02 0.02 0.02 0.02
ERY 20 (33.9) 13 (36.1) 4 (8.2) 5 (12.2)
CLI 16 (27.1) 11 (30.6) 3 (6.1) 5 (12.2)
CHL 2 (3.4) 1 (2.8) 2 (4.1) 0 (0)
SXT 16 (27.1) 5 (13.9) 8 (16.3) 7 (17.1)
TET 12 (20.3) 5 (13.9) 4 (8.2) 3 (7.3)
VAN 0 (0) 0 (0) 0 (0) 0 (0)
LVX 0 (0) 0 (0) 0 (0) 0 (0)
LZD 0 (0) 0 (0) 0 (0) 0 (0)
Table 3. Antimicrobial resistance of Streptococcus pneumoniae isolates responsible for invasive disease in 
patients <18 yrs, Portugal, July 2012–June 2015 (n = 185). aCHL: chloramphenicol; CLI: clindamycin; CRO: 
ceftriaxone; CTX: cefotaxime; ERY: erythromycin; LVX: levofloxacin; LZD: linezolid; PEN: penicillin; SXT: 
trimethoprim-sulfamethoxazole; TET: tetracycline; VAN: vancomycin. bUnless otherwise specified. cNumber 
and percentage of non-susceptible isolates is indicated.
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of a significant fraction of all pIPD cases in children and the dominance of particular serotypes in complicated 
pneumonia cases can have important consequences for the overall serotype distribution of IPD in children, as 
seen here.
The most important NVTs were 15B/C, 10A, 12B and 24F. Most of these serotypes (15B/C, 10A and 24F) were 
also among the most prevalent causes of post-PCV13 IPD in several other countries16 and were associated with 
cases of pIPD in Portugal in 2008–20121. In contrast, serotype 12B was not found among the prevalent serotypes 
elsewhere and was detected only once in pIPD in Portugal in 2008–20121, suggesting a possible recent emergence 
of a particularly virulent lineage.
The PCV7 serotypes, particularly serotype 14, remained the most important serotypes responsible for antimi-
crobial resistance, suggesting that this may be a factor driving their persistence. Relative to the previous period1 
resistance decreased only modestly, despite the sharp decrease of serotype 19A, a PCV13 serotype which was 
associated with resistance. Asymptomatic carriage with PCV13 serotypes was common in Portugal before the use 
of PCV13, although it was subject to temporal fluctuations18. However, the efficacy of vaccines in eradicating col-
onization, and therefore in reducing exposure, is known to vary between vaccine serotypes. For instance, despite 
being targeted by all PCVs available to date, serotype 19F remained common in nasopharyngeal carriage in 
children in Portugal in the late post-PCV7 period19 and in the post-PCV13 period20, including among vaccinated 
children. Such differences may mean that the overall exposure of children to certain serotypes is not significantly 
changed, potentially playing an important role in their persistence as causes of pIPD among both vaccinated and 
unvaccinated children. Besides their continued circulation in carriage, another important factor to consider is the 
different invasive disease potential of distinct serotypes, measuring their propensity to cause pIPD. In the case of 
serotypes 19A and 14, only the latter was shown to have an enhanced invasive disease potential when taken as a 
whole, although lineages with variable invasive disease potential were found within both serotypes21.
Our study has several limitations. The study was not designed to collect information important to assess the 
severity of the infections caused by the different serotypes (e.g. hospitalization, ICU admission, 30-day mortality) 
nor the vaccination status of the cases, which would be important to identify vaccine failures. We believe that few 
cases of confirmed pIPD were diagnosed outside of our network since the criteria for the identification of a pIPD 
case are the isolation of pneumococci or the identification of pneumococcal DNA in normally sterile fluids, tests 
which are almost exclusively performed in hospital laboratories. The stability of our surveillance network, the 
active nature of the surveillance and the involvement of both pediatric and microbiology departments of many 
hospitals covering the entire country, further substantiates the identification of most cases by our surveillance. We 
cannot guarantee that the serotype distribution of the cases where isolates were unavailable followed the serotype 
distribution of available isolates. However, the small proportion of cases with unknown serotype information 
ensures that our extrapolation will not greatly affect the results.
Following the substantial declines in PCV13 pIPD seen previously1, these serotypes have not declined further 
and remain the most important causes of pIPD (Fig. 2). The persistence of these serotypes, including the PCV7 
serotypes that have been subject to vaccine pressure for more than a decade, suggests that their persistence could 
be due in part to the relatively moderate vaccination uptake in Portugal. Uptake reached 75% around 20081 but 
declined to 61% in recent years13, a significantly lower uptake than in countries where PCVs are in the NIP and 
highlighting the potential benefits of increasing vaccination uptake. Continued surveillance will monitor the 
extent of VT resilience and will clarify if the vaccine failures seen with serotype 3 and its rise to most important 
pIPD serotype will be maintained following the introduction of PCV13 in the NIP, when a high vaccine uptake 
(≥95%) is expected.
Materials and Methods
Bacterial isolates. Since 2007, the Portuguese Group for the Study of Streptococcal Infections and the 
Portuguese Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society have mon-
itored pneumococcal invasive infections in Portugal. The study was approved by the Institutional Review Board 
of the Centro Académico de Medicina de Lisboa. These were considered surveillance activities and were exempt 
from informed consent. All methods were performed in accordance with the relevant guidelines and regulations. 
The data and isolates were de-identified so that these were irretrievably unlinked to an identifiable person. During 
the surveillance period this involved the microbiology laboratories and pediatric departments of 55 hospitals 
throughout Portugal. All centers reported during the entire period. A case of IPD was defined as a person from 
whom an isolate of S. pneumoniae was recovered from a normally sterile body site (not including middle ear fluid) 
or from whom pneumococcal DNA was detected in cerebrospinal fluid (CSF) or pleural fluid. Isolates recovered 
up to June 2012 were previously characterized1,2,12,22. Only isolates recovered from pediatric patients (<18 years) 
and recovered between July 2012 (week 26) and June 2015 (week 25) were included in the present study. Data on 
pleural fluid samples was reported previously13. Epidemiological years were defined as spanning from week 26 
to week 25 of the following year. Only one isolate from each patient in a 90-day interval was included. All strains 
were identified as S. pneumoniae by colony morphology and hemolysis on blood agar plates, optochin suscepti-
bility and bile solubility. In the case of body fluids where the detection of pneumococci was performed by molec-
ular methods, two S. pneumoniae genes (lytA and wzg) were used for bacterial identification13. Incidences were 
calculated based on the entire Portuguese population of the relevant age groups using data available from the first 
calendar year of each epidemiological year from “Instituto Nacional de Estatística” (www.ine.pt). This calculation 
assumes that all pIPD cases are treated within the 55 hospitals in our network.
Serotyping and antimicrobial susceptibility testing. Serotyping was performed by the standard cap-
sular reaction test using the chessboard system and specific sera (Statens Serum Institut, Copenhagen, Denmark). 
In cases where the diagnosis was done by molecular methods, the serotypes were also determined by PCR with 
a reaction targeting 21 serotypes13. Serotypes were classified into vaccine serotypes (VT), i.e., those included in 
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PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F), the additional three found in PCV10 relative to PCV7 (addPCV10: 
1, 5, 7F), the additional three found in PCV13 relative to PCV10 (addPCV13: 3, 6A, 19A), and non-vaccine sero-
types (NVT). Since the PCR reaction includes all PCV13 serotypes, when a serotype could not be identified this 
was grouped into the NVT group. Etest strips (AB Biodisk, Solna, Sweden) were used to determine the minimal 
inhibitory concentrations (MICs) for penicillin, cefotaxime, ceftriaxone and levofloxacin. In 2008, the Clinical 
and Laboratory Standards Institute (CLSI) changed the recommended breakpoints to those currently used to 
interpret MIC values14. Unless otherwise stated, we used the CLSI-recommended breakpoints prior to 200823 as 
epidemiological breakpoints, allowing the comparison with previous studies.
Isolates were further characterized by determining their susceptibility to erythromycin, clindamycin, vanco-
mycin, linezolid, tetracycline, trimethroprim-sulfamethoxazole and chloramphenicol by the Kirby-Bauer disk 
diffusion technique, according to the CLSI recommendations and interpretative criteria14. Macrolide resistance 
phenotypes were identified using a double disc test with erythromycin and clindamycin. Simultaneous resistance 
to erythromycin and clindamycin defines the MLSB phenotype (resistance to macrolides, lincosamides and strep-
togramin B) while non-susceptibility only to erythromycin indicates the M phenotype.
Statistical analysis. Simpson’s index of diversity (SID) and respective 95% confidence intervals (CI95%) 
was used to measure serotype diversity24. The Cochran-Armitage test was used for trends with the false discovery 
rate (FDR) correction for multiple testing25. A p < 0.05 was considered significant for all tests.
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable re-
quest.
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